Cannapharmarx (CPMD) AI Stock Analysis

• Market Cap: $2.09M
• Dividend Yield: N/A
• Average Volume (3M): 217.46K
• Price to Earnings (P/E): ―
• Beta (1Y): -4764.91
• Revenue Growth: N/A
• EPS Growth: -797.73%
• Country: US
• Employees: 26
• Sector: Healthcare
• Sector Strength: 54
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.03
• Shares Outstanding: 662,501,400
• 10 Day Avg. Volume: 406,105
• 30 Day Avg. Volume: 217,458
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 11.29
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -359.38
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Cannapharmarx presents a high-risk investment due to severe financial instability, reflected in negative equity and cash flow issues. The absence of technical analysis indicators further adds uncertainty. Without any positive valuation metrics or corporate events to offset the risks, the stock score is significantly low.

Cannapharmarx Business Overview & Revenue Model

Company Description

CannaPharmaRx, Inc. (CPMD) is a company engaged in the cannabis industry, focusing on the development and management of cannabis cultivation facilities. The company operates primarily in sectors related to the production and sale of medical and recreational cannabis. Its core services include the acquisition and development of state-of-the-art cultivation facilities to produce high-quality cannabis products.

How the Company Makes Money

CannaPharmaRx makes money through the cultivation and sale of cannabis products. The company's revenue model is based on the production of cannabis in its owned and managed facilities, which is then sold in both medical and recreational cannabis markets. Key revenue streams include wholesale distribution to licensed dispensaries and partnerships with other cannabis brands for product development and distribution. The company may also generate income through strategic partnerships and joint ventures that expand its market reach and optimize its production capabilities.

Cannapharmarx Financial Statement Overview

Summary

Cannapharmarx is facing significant financial challenges, including operational inefficiencies, high leverage, and liquidity constraints. The company has negative stockholders' equity and relies heavily on financing to maintain liquidity, which is unsustainable.

Income Statement

The company has experienced significant volatility in its profitability metrics. Despite a positive net income in the latest TTM (Trailing-Twelve-Months), there are substantial negative values in gross profit, EBIT, and EBITDA, indicating ongoing operational challenges. The lack of revenue in previous periods also suggests a potential for inconsistent revenue streams.

Balance Sheet

The balance sheet reflects high financial leverage, with a negative stockholders' equity and a debt-to-equity ratio that cannot be calculated due to negative equity. The company's liabilities exceed its assets significantly, indicating financial instability and potential solvency issues.

Cash Flow

Cash flow analysis shows negative operating and free cash flows, pointing to challenges in generating cash from operations. The company relies heavily on financing activities to maintain liquidity, which may not be sustainable in the long term.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
-65.56K	-294.93K	-14.36K	-128.50K	-129.03K
	EBIT
-1.58M	-5.21M	-2.99M	-14.49M	-15.98M
	EBITDA
-1.45M	-4.91M	-2.61M	-17.47M	-2.85M
	Net Income Common Stockholders
3.69M	-8.53M	-10.34M	-22.18M	-24.92M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
650.00	2.32K	27.77K	334.97K	1.55K
	Total Assets
11.75M	5.41M	114.33K	8.75M	16.02M
	Total Debt
12.94M	14.52M	9.02M	10.00M	9.28M
	Net Debt
12.93M	14.52M	8.99M	9.67M	9.28M
	Total Liabilities
23.90M	22.76M	13.04M	17.55M	11.16M
	Stockholders Equity
-12.15M	-17.34M	-12.93M	-8.80M	4.85M
Cash Flow		Free Cash Flow
-2.36M	-1.56M	-2.42M	-563.57K	-3.84M
	Operating Cash Flow
-2.27M	-1.45M	-2.41M	-563.57K	-3.79M
	Investing Cash Flow
-80.63K	-116.00K	493.62K	0.00	-46.94K
	Financing Cash Flow
2.35M	1.40M	1.30M	824.57K	3.27M

Cannapharmarx Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.21B	3.54	-41.91%	2.83%	15.15%	0.55%
APDN	42 Neutral	$5.65M	―	-100.40%	―	-58.46%	47.98%
SHPH	32 Underperform	$1.71M	―	-383.84%	―	―	-7.18%
BJDX	29 Underperform	$2.63M	―	-178.98%	―	―	81.35%
HCTI	27 Underperform	$8.73M	―	-292.41%	―	-64.77%	43.53%
CPMD	17 Underperform	$2.09M	―	-8.32%	―	―	-797.73%

Cannapharmarx Corporate Events

Cannapharmarx Appoints Constantine Nkafu as Interim CEO

Cannapharmarx has appointed Constantine Nkafu as the interim CEO, who has been managing the company’s operations for several months. Nkafu, who also serves as the CEO of a subsidiary, brings extensive experience in the pharmaceutical, cannabis, and medical device industries, and has been instrumental in setting up and running complex operations. In addition, the company has appointed Amir Tal, Constantine Nkafu, and Elliot Zemel to its Board of Directors as part of an agreement with LTB Management, LLC. Nkafu and Zemel, both authorized by Health Canada to serve as directors, bring significant expertise and networks in the cannabis industry, which could enhance the company’s strategic positioning.